A Phase 1b, Open-label, Multi-cohort Study of AZD0120, an Autologous CD19/BCMA Targeting Chimeric Antigen Receptor T-cell, in Adults With Autoimmune Diseases
AstraZeneca's AZD0120 is positioned in the emerging CAR T-cell therapy market, targeting autoimmune diseases such as systemic sclerosis, idiopathic inflammatory myopathies, and difficult-to-treat rheumatoid arthritis. The dual targeting mechanism may provide a competitive edge over existing therapies, particularly in indications with high unmet needs. The trial's multi-cohort design allows for the exploration of efficacy across different autoimmune conditions, potentially expanding the market reach. Given the increasing prevalence of autoimmune diseases and the limitations of current treatments, successful outcomes could lead to significant commercial opportunities. However, the presence of established competitors in the CAR T-cell space necessitates careful monitoring of trial results and market dynamics.
Indication: Systemic Sclerosis
Modality: cell therapy
Target: CD19 and BCMA dual targeting via Chimeric Antigen Receptor T-cell therapy
Sponsor: AstraZeneca
Source URL: ClinicalTrials.gov
Source updated: Detailed source ingestion pending
Ingested: Jul 22, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: CD19 and BCMA dual targeting via Chimeric Antigen Receptor T-cell therapy
View original source fields
Condition raw: Systemic Sclerosis, Idiopathic Inflammatory Myopathies, Rheumatoid Arthritis
Condition normalized: Systemic Sclerosis, Idiopathic Inflammatory Myopathies, Rheumatoid Arthritis
Modality raw: cell therapy
Modality normalized: cell therapy
Target raw: CD19 and BCMA dual targeting via Chimeric Antigen Receptor T-cell therapy
Target normalized: CD19 and BCMA dual targeting via Chimeric Antigen Receptor T-cell therapy